IMRNW (Immuron) Debt-to-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Immuron Debt-to-Asset?

Immuron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.03 Mil. Immuron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.09 Mil. Immuron's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $10.33 Mil. Immuron's debt to asset for the quarter that ended in Jun. 2024 was 0.01.

Immuron Debt-to-Asset Historical Data

The historical data trend for Immuron's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Debt-to-Asset Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Asset

Get a 7-Day Free Trial

0.01

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial													0.01	0.01	0.01	-	0.01

Competitive Comparison of Immuron's Debt-to-Asset

For the Biotechnology subindustry, Immuron's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Immuron's Debt-to-Asset falls into.

Immuron Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Immuron's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.027	+	0.088)	/	10.325
	=	0.01

Immuron's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.027	+	0.088)	/	10.325
	=	0.01

Immuron (NAS:IMRNW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Immuron Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Immuron's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRNW) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany ANWA:Germany ANW:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.